Mary-Katherine Monahan

Title: The Innovative Contributions of Mary-Katherine Monahan

Introduction

Mary-Katherine Monahan is a distinguished inventor based in Hamden, Connecticut. She has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for diseases mediated by specific kinases. With a total of five patents to her name, her work has had a notable impact on medical research and therapeutic applications.

Latest Patents

Among her latest patents, one notable invention is the "Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas." This invention focuses on the use of a group of aryl ureas in treating RAF-mediated diseases, along with pharmaceutical compositions designed for such therapies. Another significant patent is for "ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors." This invention also relates to the use of aryl ureas, specifically targeting p38-mediated diseases and the pharmaceutical compositions that can be utilized in these treatments.

Career Highlights

Mary-Katherine has worked with prominent companies in the pharmaceutical industry, including Bayer Pharmaceuticals Corporation and Bayer Healthcare LLC. Her experience in these organizations has allowed her to contribute to groundbreaking research and development in the field of medicine.

Collaborations

Throughout her career, Mary-Katherine has collaborated with esteemed colleagues such as Bernd Riedl and Jacques P. Dumas. These partnerships have further enhanced her innovative work and expanded the reach of her inventions.

Conclusion

Mary-Katherine Monahan's contributions to the field of pharmaceuticals through her innovative patents and collaborations highlight her role as a leading inventor. Her work continues to influence the development of effective treatments for various diseases.